Table 2.
Prognostic factors for overall survival and recurrence-free survival.
| Variable | Overall survival | Recurrence-free survival | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| Age> 55 y | 1.13 (0.48-2.67) | 0.784 | 0.76 (0.42-1.37) | 0.354 | ||||
| Male | 0.68 (0.28-1.62) | 0.380 | 0.42 (0.23-0.77) | 0.005 | ||||
| Primary tumor | ||||||||
| Rectum cancer | 0.87 (0.35-2.17) | 0.762 | 0.56 (0.28-1.14) | 0.112 | ||||
| T3/T4 stage | 0.76 (0.10-5.79) | 0.789 | 1.50 (0.36-6.23) | 0.581 | ||||
| N1/N2 stage | 1.98 (0.63-6.20) | 0.240 | 1.16 (0.60-2.26) | 0.658 | ||||
| TNM III/IV stage | 0.99 (0.55-1.77) | 0.962 | 1.19 (0.79-1.80) | 0.402 | ||||
| Resection with CRLM | 0.65(0.24-1.80) | 0.410 | 0.85 (0.46-1.57) | 0.608 | ||||
| CRLM | ||||||||
| Synchronous metastases | 1.13 (0.41-3.11) | 0.817 | 1.12 (0.52-2.40) | 0.781 | ||||
| CEA > 200 μg/L | 1.25 (0.17-9.51) | 0.827 | 1.11 (0.39-3.10) | 0.850 | ||||
| CA19-9> 35 kU/L | 3.67 (1.55-8.70) | 0.003∗ | 4.29 (1.77-10.37) | 0.001∗ | 1.40 (0.74-2.60) | 0.302 | ||
| Tumor number in image >5 | 1.12 (0.47-2.68) | 0.799 | 1.27 (0.70-2.29) | 0.436 | ||||
| Tumor number in surgery >5 | 1.90 (0.78-4.63) | 0.158 | 1.95 (1.07-3.56) | 0.030∗ | 1.95 (1.07-3.56) | 0.030∗ | ||
| More tumor number than image | 2.61 (1.08-6.28) | 0.027∗ | 3.19 (1.28-7.97) | 0.013∗ | 1.62 (-/88-2.97) | 0.122 | ||
| Tumor size >5cm | 4.36 (0.96-19.7) | 0.056 | 1.57 (0.56-4.42) | 0.392 | ||||
| R0 resection | 2.06 (0.66-6.41) | 0.211 | ||||||
| CRS score 3-5 | 1.63 (0.68-3.91) | 0.276 | 1.18 (0.65-2.15) | 0.580 | ||||
HR = hazard ratio; CI = confidence interval; T stage = tumor stage; N stage = node stage; TNM stage = tumor node metastasis stage; CRLM = colorectal liver metastases; CEA = carcinoembryonic antigen; CA19-9 = carbohydrate antigen 19-9; R0 resection = hepatectomy on patients with clear histological margins; CRS = clinical risk score; ∗P < 0.05.